TwoStep Therapeutics
A peptide-targeting platform is advancing conjugate and radioligand therapies for solid tumors.
$62.5MSeries A
Role not disclosedIP
Insight Partners
Activity from announced rounds
Activity in this selectionOct 24, 2026 · Biotech · Jul 27, 2026
Insight Partners invests in software companies from early stages through growth and later-stage expansion, with an operating team focused on the work of scaling a software business.
Its Onsite team provides specialist support in hiring, marketing, product, acquisitions and international expansion. Founders can work with operators on questions such as building a sales organisation, recruiting leadership and improving growth efficiency.
Insight’s model is particularly relevant when a company is turning product-market fit into a repeatable business. Its investment platform can address both the capital needed for expansion and the organisational changes that accompany it.
Sources
- Rounds participated in
- 2
- Confirmed lead rounds
- 0 1 roles undisclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $122.5M 2 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
2 in this selectionSuperluminal Medicines
Superluminal Medicines combines structural biology, protein dynamics, machine learning and experimental testing to discover small-molecule drugs for difficult G protein-coupled receptor targets. Its pipeline focuses on endocrine and cardiometabolic diseases, including rare genetic and hypothalamic obesity.
$60MSeries B
Participant